Clinical trial · Interventional
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neoadjuvant chemotherapy is alternative treatment option to upfront cytoreductive surgery to treat advanced ovarian cancer. Paclitaxel plus carboplatin is most frequently selected chemotherapeutic regimen for neoadjuvant chemotherapy. Docetaxel had similar therapeutic efficacy compared to paclitaxel in adjuvant chemotherapy trials in ovarian cancer. However, docetaxel had more favorable toxicity profile. Therefore, the investigators aimed to evaluate the efficacy of docetaxel plus carboplatin as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Neoadjuvant chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy
- description
- Neoadjuvant chemotherapy with docetaxel plus carboplatin
- interventionNames
- Drug: Neoadjuvant chemotherapy
- Drug: Carboplatin
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 1 month after completion of study treatment
Secondary outcomes (4)
- measure
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- timeFrame
- Before each chemotherapy, an average of 3 week
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced epithelial, tubal, or primary peritoneal cancer * Cancer cells in paracentesis, thoracentesis, or laparoscopic surgery * Less probability of complete cytoreduction * Age: 20-80 years * GOG performance status: 0-3 * Adequate organ function Bone marrow: ANC ≥ 1,500mm3, Platelet ≥ 100,000/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine ≤ 1.25 × UNL Liver: AST, ALT ≤ × 2.5 UNL (in case of liver metastasis, AST, ALT ≤ × 5 UNL), alkaline phosphatase ≤ 5 x UNL, bilirubin ≤ 1.5 mg/ mm3 Exclusion Criteria: * Previous chemotherapy or pelvic radiation therapy * Final diagnosis is other malignancies * Coincidental Other malignancies within 5 years except carcinoma in situ of uterine cervix * History of severe allergy * Pregnancy, lactating woman * Uncontrolled medial disease * Bowel obstruction requiring immediate surgery * Etc.
References
Publications (0)
Data not yet available